Merck Serono, Galderma breach ABPI code; Health Canada hands-off when regulating DTC drug ads, study finds;

> The Prescription Medicines Code of Practice Authority has found Merck KGaA's Serono unit and Galderma guilty of the most serious breach of the ABPI Code of Practice. Report

> Health Canada is indifferent to enforcing its own regulations when it comes to prescription drug ads targeted to health consumers, a new study has found. Report

> If the total number of new HCV patients doubles in 2014, there will be room for the forthcoming crop of hep C competitors, a Morgan Stanley analyst says. More

> Sun Pharma may retire the Ranbaxy brand while retaining sub-brands like Volini and Revital. Report

> Novartis' ($NVS) Sandoz biosimilar copy of Amgen's ($AMGN) Neupogen showed similar efficacy in a late-stage study. Report

> Barnum Communications founder Dr. James Barnum and Lewis and Gace cofounder Francis Gace have been selected as 2015 inductees into the Medical Advertising Hall of Fame. Story

And Finally... BlackBerry is targeting doctors and nurses who use its smartphones with its first healthcare app. More

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.